Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

14.42
+0.38002.71%
Post-market: 14.420.00000.00%18:39 EDT
Volume:1.40M
Turnover:20.42M
Market Cap:1.98B
PE:-2.80
High:14.97
Open:14.23
Low:14.22
Close:14.04
Loading ...

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of Aro-Alk7 for the Treatment of Obesity

THOMSON REUTERS
·
03 Dec 2024

ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…

Zacks Small Cap Research
·
03 Dec 2024

Arrowhead price target lowered to $24 from $27 at Bernstein

TipRanks
·
30 Nov 2024

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR) and Sanofi (OtherSNYNF)

TIPRANKS
·
29 Nov 2024

Sarepta price target lowered to $202 from $205 at Needham

TipRanks
·
28 Nov 2024

Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance

TIPRANKS
·
28 Nov 2024

Q4 2024 Arrowhead Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
28 Nov 2024

SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies

Zacks
·
28 Nov 2024

Arrowhead Stock Rockets 16% After Major Licensing Deal

GuruFocus.com
·
28 Nov 2024

Arrowhead Pharmaceuticals Shares up 6.2% ; at Least Two Brokerages Raise PT After Licensing Deal With Sarepta

THOMSON REUTERS
·
27 Nov 2024

BUZZ-Arrowhead Pharma gains as two brokerages raise PT after Sarepta deal

Reuters
·
27 Nov 2024

Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
27 Nov 2024

Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments

TipRanks
·
27 Nov 2024

Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board

TipRanks
·
27 Nov 2024

RBC Capital Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
27 Nov 2024

Piper Sandler Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
27 Nov 2024

Arrowhead Pharmaceuticals : Piper Sandler Cuts Target Price to $45 From $62

THOMSON REUTERS
·
27 Nov 2024

Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ...

GuruFocus.com
·
27 Nov 2024

Strategic Reprioritization and Partnership Propel Arrowhead Pharmaceuticals’ Growth Prospects

TIPRANKS
·
27 Nov 2024

Arrowhead Pharmaceuticals Eyes Future Growth with Strategic Deals

TIPRANKS
·
27 Nov 2024